Trial Profile
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antineoplastics; Rituximab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms RoZetta
- 15 Jul 2013 Status changed from recruiting to discontinued, as the sponsor decided to terminate the study, according to the ClinicalTrials.gov record.
- 07 Feb 2013 New source identified and integrated (Mayo Clinic record: 12-008679).
- 20 Aug 2012 New trial record